These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24506246)

  • 1. CD133-positive stem cells.
    Bian EB; Li J; Zhao B
    J Neurosurg; 2014 Apr; 120(4):1011-2. PubMed ID: 24506246
    [No Abstract]   [Full Text] [Related]  

  • 2. CD133-positive stem cells. Response.
    Tamura K; Aoyagi M
    J Neurosurg; 2014 Apr; 120(4):1012. PubMed ID: 24809085
    [No Abstract]   [Full Text] [Related]  

  • 3. Stem cells and the origin of different glioma subtypes.
    Roesler R
    J Neurosurg; 2014 Apr; 120(4):1009-10. PubMed ID: 24506242
    [No Abstract]   [Full Text] [Related]  

  • 4. Stem cells and the origin of different glioma subtypes. Response.
    Tamura K; Aoyagi M
    J Neurosurg; 2014 Apr; 120(4):1010-1. PubMed ID: 24809083
    [No Abstract]   [Full Text] [Related]  

  • 5. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
    Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
    J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells.
    Qin K; Tian G; Li P; Chen Q; Zhang R; Ke YQ; Xiao ZC; Jiang XD
    J Neuroimmunol; 2012 Jan; 242(1-2):9-15. PubMed ID: 22123613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
    Brown CE; Starr R; Martinez C; Aguilar B; D'Apuzzo M; Todorov I; Shih CC; Badie B; Hudecek M; Riddell SR; Jensen MC
    Cancer Res; 2009 Dec; 69(23):8886-93. PubMed ID: 19903840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.
    Wolpert F; Roth P; Lamszus K; Tabatabai G; Weller M; Eisele G
    J Neuroimmunol; 2012 Sep; 250(1-2):27-34. PubMed ID: 22688424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
    Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ultrastructural difference between CD133-positive U251 glioma stem cells and normal U251 glioma cells.
    Yang B; Wang Y; Yang C; Ouyang W; Zhou F; Zhou Y; Xie C
    Ultrastruct Pathol; 2012 Dec; 36(6):404-8. PubMed ID: 23216238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Neural Killer" Cells: Autologous Cytotoxic Neural Stem Cells for Fighting Glioma.
    Mutukula N; Elkabetz Y
    Cell Stem Cell; 2017 Apr; 20(4):426-428. PubMed ID: 28388425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
    Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
    Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
    Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
    Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
    Nagata T; Sakakura C; Komiyama S; Miyashita A; Nishio M; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
    Anticancer Res; 2011 Feb; 31(2):495-500. PubMed ID: 21378329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.